XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

被引:5
|
作者
Yang, Qi [1 ]
Wei, Yan-Fei [2 ]
Zhang, Yuan [3 ]
Huang, Guang-Mei [4 ]
机构
[1] Tianjin Fifth Cent Hosp, Dept Emergency, Binhai New Area, Tianjin 300450, Peoples R China
[2] Guangxi Univ Chinese Med, Dept Physiol, Nanning 530001, Guangxi, Peoples R China
[3] Fourth Mil Med Univ, Xijing Dermatol Hosp, Dept Lab, Xian 710032, Shaanxi, Peoples R China
[4] Guigang Peoples Hosp, Dept Anesthesiol, Guigang 537100, Guangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
xeroderma pigmentosum complementary group D polymorphisms; hepatocellular carcinoma; Lys(751)Gln; Asp(312)Asn; meta-analysis; PROSTATE-CANCER RISK; REPAIR GENE POLYMORPHISMS; HEPATITIS-B; ASSOCIATION; ASP312ASN; LYS751GLN; VARIANTS; XRCC1;
D O I
10.3892/etm.2015.2421
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This meta-analysis was performed to evaluate the association between xeroderma pigmentosum complementary group D (XPD) Lys(751)Gln and Asp(312)Asn polymorphisms and susceptibility to hepatocellular carcinoma (HCC). PubMed, Embase, Google Scholar and the Chinese National Knowledge Infrastructure and the Chinese Biomedicine databases were systematically searched to identify relevant studies published up to June 1, 2014. Statistical analyses were performed using Stata version 12.0 software. A total of 11 case-control studies, comprising 2,852 cases and 2,936 controls, were included. The results of the meta-analysis revealed that a significant association between the risk of HCC and variant genotypes of the XPD Lys(751)Gln and Asp(312)Asn polymorphisms was evident in the homozygote comparison [Gln/Gln versus Lys/Lys: Odds ratio (OR), 1.831; 95% confidence interval (CI), 1.001-3.349], heterozygote comparison (Lys/Gln versus Lys/Lys: OR, 1.486; 95% CI, 1.044-2.114), dominant model (Gln/Gln + Lys/Gln versus Lys/Lys: OR, 1.540; 95% CI, 1.054-2.249) and allelic contrast (Gln-allele versus Lys-allele: OR, 1.453; 95% CI, 1.032-2.046) for the Lys(751)Gln polymorphism and the homozygote comparison for the Asp(312)Asn polymorphism (Asn/Asn versus Asp/Asp: OR, 1.352; 95% CI, 1.010-1.808). By contrast, no significant association was observed in the recessive model for the Lys(751)Gln polymorphism (Gln/Gln versus Lys/Gln + Lys/Lys: OR, 1.603; 95% CI, 0.924-2.779), or for the heterozygote comparison (Asn/Asp versus Asp/Asp: OR, 1.229; 95% CI, 0.857-1.762), dominant model (Asn/Asn + Asp/Asn versus Asp/Asp: OR, 1.249; 95% CI, 0.910-1.715), recessive model (Asn/Asn versus Asp/Asn + Asp/Asp: OR, 1.250; 95% CI, 0.940-1.663) or allelic contrast (Asn-allele versus Asp-allele: OR, 1.226; 95% CI, 0.965-1.557) for the Asp(312)Asn polymorphism. The present meta-analysis has indicated that the XPD Lys(751)Gln polymorphism could be a potential biomarker of HCC susceptibility and that the XPD Lys(751)Gln and Asp(312)Asn polymorphisms could be risk factors for HCC susceptibility in an Asian population; however, further large-scale and well-designed studies are required to reach a more precise and comprehensive conclusion.
引用
收藏
页码:2406 / 2414
页数:9
相关论文
共 50 条
  • [1] XPD Lys751Gln and Asp312Asn Polymorphisms and Gastric Cancer Susceptibility: A Meta-analysis of Case-control Studies
    Yin, Qing-Hua
    Liu, Chuan
    Hu, Jian-Bing
    Meng, Rong-Rong
    Li, Lian
    Wang, Ya-Jie
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (01) : 231 - 236
  • [2] XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies
    Zhu, Hai-Li
    Bao, Ji-Ming
    Lin, Pei-Xin
    Li, Wen-Xia
    Zou, Zhen-Ning
    Huang, Ye-En
    Chen, Qing
    Shen, Hong
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) : 6619 - 6625
  • [3] XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis
    Yan, Yulan
    Liang, Hongjie
    Light, Morning
    Li, Taijie
    Deng, Yan
    Li, Meng
    Li, Shan
    Qin, Xue
    TUMOR BIOLOGY, 2014, 35 (03) : 1907 - 1915
  • [4] XPD Lys751Gln and Asp312Asn polymorphisms and bladder cancer risk: a meta-analysis
    Li, Chunxiang
    Jiang, Zheng
    Liu, Xinghan
    MOLECULAR BIOLOGY REPORTS, 2010, 37 (01) : 301 - 309
  • [5] XPD Lys751Gln and Asp312Asn polymorphisms and bladder cancer risk: a meta-analysis
    Chunxiang Li
    Zheng Jiang
    Xinghan Liu
    Molecular Biology Reports, 2010, 37 : 301 - 309
  • [6] Association Between XPD Lys751Gln and Asp312Asn Polymorphisms and Hepatocellular Carcinoma Risk A Systematic Review And Meta-Analysis
    Peng, Qiliu
    Li, Shan
    Lao, Xianjun
    Chen, Zhiping
    Li, Ruolin
    Qin, Xue
    MEDICINE, 2014, 93 (29) : e330
  • [7] Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies
    Zhang, Ying
    Ding, Dapeng
    Wang, Xiaoxue
    Zhu, Zhenglan
    Huang, Meiyan
    He, Xiaofeng
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (10) : 1257 - 1264
  • [8] Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case–control studies
    Ying Zhang
    Dapeng Ding
    Xiaoxue Wang
    Zhenglan Zhu
    Meiyan Huang
    Xiaofeng He
    International Journal of Colorectal Disease, 2011, 26 : 1257 - 1264
  • [9] Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer
    Noel Pabalan
    Ofelia Francisco-Pabalan
    Lillian Sung
    Hamdi Jarjanazi
    Hilmi Ozcelik
    Breast Cancer Research and Treatment, 2010, 124 : 531 - 541
  • [10] Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer
    Pabalan, Noel
    Francisco-Pabalan, Ofelia
    Sung, Lillian
    Jarjanazi, Hamdi
    Ozcelik, Hilmi
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) : 531 - 541